We are live on ! Find out more
SOCM

SR One Capital Management Portfolio holdings

AUM $915M
1-Year Est. Return 209.71%
This Fund
S&P 500
This Quarter Est. Return
+18.4%
1 Year Est. Return
+209.71%
3 Year Est. Return
+484.66%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$461M
AUM Growth
+$72.1M
Cap. Flow
+$30.3M
Cap. Flow %
6.57%
Top 10 Hldgs %
97.75%
Holding
13
New
1
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
ORIC icon
Oric Pharmaceuticals
ORIC
+$30.3M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACLX
1
DELISTED
Arcellx
ACLX
$155M 33.49%
2,346,630
– –
SPRY icon
2
ARS Pharmaceuticals
SPRY
$591M
$70M 15.18%
4,012,903
– –
CRSP icon
3
CRISPR Therapeutics
CRSP
$5.23B
$51M 11.06%
1,048,951
– –
ZBIO
4
Zenas BioPharma
ZBIO
$2.05B
$47.6M 10.32%
4,911,539
– –
ORIC icon
5
Oric Pharmaceuticals
ORIC
$1.42B
$45.8M 9.93%
+4,514,929
New +$30.3M
MLYS icon
6
Mineralys Therapeutics
MLYS
$2.41B
$42.3M 9.17%
3,127,933
– –
DSGN icon
7
Design Therapeutics
DSGN
$915M
$22M 4.77%
6,526,476
– –
OCS icon
8
Oculis Holding
OCS
$708M
$6.26M 1.36%
322,500
– –
ALMS
9
Alumis Inc
ALMS
$3.23B
$5.88M 1.27%
1,959,896
– –
NKTX icon
10
Nkarta
NKTX
$167M
$5.53M 1.2%
3,333,333
– –
ORKA
11
Oruka Therapeutics
ORKA
$6.31B
$4.82M 1.05%
430,330
– –
KALA icon
12
KALA BIO
KALA
$16.3M
$2.85M 0.62%
11,979
– –
ENGN icon
13
enGene Therapeutics
ENGN
$122M
$2.72M 0.59%
747,750
– –

Similar funds

PTC
Petrus Trust Company Dallas, Texas $915M AUM 2.95% 1-Year Est. Return
SC
Sierra Capital Miami, Florida $918M AUM 8.25% 1-Year Est. Return
SI
Symmetry Investments St Helier, Jersey $913M AUM 30.59% 1-Year Est. Return
GIG
Goodnow Investment Group Darien, Connecticut $913M AUM 11.84% 1-Year Est. Return
SAA
Southeast Asset Advisors Thomasville, Georgia $913M AUM 25.32% 1-Year Est. Return
GC
Greenvale Capital London, United Kingdom $912M AUM 34.2% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
FFL
Flat Footed LLC Wilson, Wyoming $920M AUM 86.47% 1-Year Est. Return

SR One Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, SR One Capital Management held 13 positions worth $461M, up 19% from $389M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

SR One Capital Management deployed $30.3M of net new capital in Q2 2025, opening 1 new position. Its largest new stake was Oric Pharmaceuticals: 4,514,929 shares worth $45.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • SR One Capital Management's largest Q2 2025 buy was Oric Pharmaceuticals: 4,514,929 shares worth $45.8M.
  • SR One Capital Management's ten largest holdings make up 98% of its $461M portfolio in Q2 2025.
  • SR One Capital Management opened 1 new position and closed 0 in Q2 2025.
  • SR One Capital Management's portfolio value rose 19% quarter-over-quarter to $461M.

Based on SR One Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.